Yahoo Finance

TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial

BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- TearClear, a late clinical stage ophthalmic pharmaceutical company, is pleased to announce the TC-002 Phase 3 trial has been successfully initiated. TearClear ...
Yahoo Finance

TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)

CHICAGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced today that the company's lead ...
Business Wire

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ...
Healio

Global studies find latanoprost more effective than timolol

UPPSALA, Sweden — Latanoprost (Xalatan, Pharmacia Corp.) reduced diurnal intraocular pressure (IOP) significantly more than timolol, according to a meta-analysis of eight global randomized trials, ...
Medical News Today

Latanoprost and cost

Latanoprost is a generic prescription medication. The Food and Drug Administration (FDA) has approved it to treat increased pressure in the eyes. The drug is for use in adults who have either ...